Bioventix (LON:BVXP – Get Free Report) announced its earnings results on Monday. The biotechnology company reported GBX 145.74 earnings per share for the quarter, Digital Look Earnings reports. The firm had revenue of GBX 1,297 million during the quarter. Bioventix had a net margin of 59.30% and a return on equity of 65.83%.
Bioventix Price Performance
BVXP stock opened at GBX 1,962 on Tuesday. The stock has a market capitalization of £102.51 million, a P/E ratio of 13.96 and a beta of 0.54. The business has a 50-day moving average of GBX 1,694.82 and a 200-day moving average of GBX 1,656.41. Bioventix has a fifty-two week low of GBX 1,300 and a fifty-two week high of GBX 2,255.
Bioventix Company Profile
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.
Read More
- Five stocks we like better than Bioventix
- GXO Logistics Is Turning Warehouse Robots Into a Growth Strategy
- A Solid Margin Story Means the Sell-Off in DECK May Be Overdone
- Verizon’s Q3 Results Show Why SpaceX’s Spectrum Grab Isn’t a Major Threat
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
Receive News & Ratings for Bioventix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventix and related companies with MarketBeat.com's FREE daily email newsletter.
